Bayer’s Defining Summer: A Supreme Court Ruling and a $7.25bn Settlement Hearing Converge
Published on 06/18/2026 at 07:34 | Redaktion boerse-global.de
The legal fog that has hung over Bayer for years is about to lift — or thicken — in rapid succession. This week the US Supreme Court is expected to hand down its verdict in the pivotal Monsanto v. Durnell case, while a separate federal judge has already scheduled a July 9 hearing to approve a landmark $7.25 billion class-action settlement covering future Roundup claims. Together, the two events could reshape the pharmaceutical and agricultural giant’s litigation landscape for good.
The Supreme Court decision, widely anticipated by late June, turns on a fundamental pre?emption question: can state?law verdicts stand when the US Environmental Protection Agency has deemed a product safe? A win for Bayer would effectively neutralise the bulk of roughly 65,000 remaining glyphosate?related lawsuits. UBS puts the probability of a favourable outcome at about 70%, but warns that if the court rules against the group and the case lands back with California judge Vince Chhabria — considered an unfriendly venue — the theoretical floor for the stock sits at €28.00. The bank maintains its “Buy” rating and €52.00 target.
Meanwhile, the $7.25 billion settlement — which aims to cover future claims linking Roundup to non?Hodgkin lymphoma — has been sent back to a federal court in St. Louis for final approval. Bayer welcomed the procedural move, calling it “long?awaited clarity”. The crucial hearing is set for 9 July 2026.
Away from the courtroom, Bayer has been busy shoring up its pipeline. On Wednesday it completed the acquisition of Perfuse Therapeutics, a Californian biotech, for an upfront payment of $300 million. Milestone?based earn?outs could push the total consideration to $2.45 billion. The deal’s centrepiece is PER?001, an intravitreal implant in Phase II trials for glaucoma and diabetic retinopathy, which strengthens Bayer’s ophthalmology portfolio.
Should investors sell immediately? Or is it worth buying Bayer?
The group’s drug development efforts also received a boost in Europe. The European Medicines Agency has validated the marketing?authorisation application for Asundexian, a Factor XIa inhibitor designed to prevent ischaemic strokes. In the Phase III OCEANIC?STROKE study, the drug cut the risk of recurrent stroke by 26% versus placebo — the first such filing for this class in Europe. China and the US have already granted priority review, and a decision from the EMA is expected within 12 to 18 months. Asundexian is being positioned as the successor to Xarelto, whose sales dropped by a third to $2.6 billion in 2025 after losing patent protection.
All this comes as Bayer welcomes a new chief financial officer. Judith Hartmann took over on 1 June, replacing Wolfgang Nickl who retired as planned. Hartmann, formerly CFO at Bertelsmann and deputy CEO at ENGIE, also held senior roles at General Electric in the US, Europe and Brazil — experience that may prove valuable as the company restructures. Bayer has halved its management layers, cut thousands of jobs, and slashed the 2025 dividend to €0.11 per share. In the first quarter alone, net cash outflows exceeded €2 billion, mostly to cover PCB and glyphosate litigation.
Further supporting the agricultural side, the European Parliament voted in favour of looser labelling rules for certain gene?editing techniques, a move that could ease the commercialisation of new seed technologies at Bayer’s crop science division.
Bayer at a turning point? This analysis reveals what investors need to know now.
For 2026, management expects stronger contributions from agriculture and consumer health to offset a weaker pharma performance, leaving overall group earnings roughly flat. The next hard data point arrives on 4 August, when second?quarter results are due.
The stock ended Thursday at €37.75, just below its 50?day moving average of €37.92. In the past seven trading sessions it has climbed 5.07%, with today’s Supreme Court ruling set to determine whether that momentum can hold — or whether the legal clouds will darken once again.
Ad
Bayer Stock: New Analysis - 18 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
